Profile for Brazil Patent: PI0619919

US Patent Family Members and Approved Drugs for Brazil Patent: PI0619919

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,278,292	Jul 6, 2027	Leo Labs	PICATO	ingenol mebutate
8,372,827	Dec 18, 2026	Leo Labs	PICATO	ingenol mebutate
8,372,828	Dec 18, 2026	Leo Labs	PICATO	ingenol mebutate
8,377,919	Dec 18, 2026	Leo Labs	PICATO	ingenol mebutate

Detailed Analysis of the Scope, Claims, and Patent Landscape for Brazil Patent BRPI0619919

---

Introduction

Brazil Patent BRPI0619919 pertains to a pharmaceutical invention aimed at addressing specific medical needs within the nation’s regulatory and industrial environment. As part of a comprehensive patent landscape analysis, understanding its scope and claims provides insights into the patent’s strength, coverage, innovation threshold, and competitive positioning. The analysis below synthesizes the scope, claims, and overall patent landscape for this patent, delivering valuable intelligence for stakeholders including pharmaceutical companies, generic manufacturers, and legal practitioners.

---

Patent Overview and Summary

Brazilian Patent BRPI0619919 was granted or filed around the early 2010s, reflecting a period of heightened pharmaceutical patent activity, particularly in areas such as formulations, therapeutic methods, and drug delivery systems. The patent is titled, broadly, to cover a novel drug composition or process—potentially involving a specific active pharmaceutical ingredient (API), a unique formulation, or a therapeutic use.

The patent’s core claims aim to establish exclusivity over an innovative pharmaceutical product, formulation method, or treatment protocol, with probable emphasis on chemical stability, bioavailability, or targeted therapeutic effects.

---

Scope and Claims Analysis

Claim Structure and Broadness

BRPI0619919's claims can be classified anatomically as follows:

• Independent Claims: These tend to define the broadest protection, often covering the core invention elements—such as a specific chemical compound, composition, or method of treatment. The independent claims likely specify the API, its derivatives, or a novel formulation feature that distinguishes it from prior art.

• Dependent Claims: These narrow the independent claims by adding particular details—such as dosage ranges, carriers, methods of manufacturing, or specific use cases—thus enhancing patent defensibility.

Scope Analysis

• Chemical and Formulation Scope: If the patent claims a chemical compound or derivative, the scope is confined to that molecule or a narrow class of similar compounds. For formulations, the claim scope encompasses specific proportions, excipients, or delivery mechanisms.

• Method of Manufacturing: Claims may also include specific steps in synthesizing the API or manufacturing the formulation, which augment enforceability.

• Therapeutic Use: Claims that cover novel therapeutic methods—e.g., a new treatment for a specific condition—are often narrower but remain critical for defending market exclusivity.

Claim Strength and Limitations

• Strengths: Broad independent claims covering the core API or formulation provide dominant commercial protection. Claims inclusive of specific manufacturing steps or use cases can prevent the entry of generics or biosimilars that deviate even slightly.

• Weaknesses: Overly broad claims risk invalidation if prior art demonstrates prior similar inventions; narrow claims, however, may be easier for competitors to design around.

---

Patent Landscape and Positioning

Prior Art and Novelty

The patent appears to be built on a foundation of earlier published chemical or pharmaceutical patents, possibly including prior art from both Brazil and international filings. The novelty likely hinges on a specific chemical modification, formulation, or unexpected therapeutic effect, which differentiates it from existing patents or publications.

Related Patents and Competitors

• Patent Families: BRPI0619919 probably forms part of a broader patent family, with corresponding applications in Europe (EPO), the US (through continuing applications or divisionals), or other jurisdictions.

• Key Competitors: Major pharmaceutical companies or biotech firms operating within Brazil or Latin America may have related patents aiming to block generic entry, collaborate, or license the technology.

• Patent Thickets: The landscape may contain overlapping patents covering similar compounds, formulations, or treatment methods, creating a dense patent environment requiring careful freedom-to-operate analysis.

Patent Term and Expiry

Brazilian patents typically last 20 years from the filing date, pending maintenance fees and patent officeia trends. The patent’s remaining term influences market strategies—whether to commercialize, license, or challenge.

---

Legal and Commercial Implications

• Enforceability and Litigation: The scope and clarity of claims determine litigation strength. Clear, well-supported claims spanning key aspects of the invention help defend against invalidation or infringement challenges.

• Market exclusivity: A broad patent scope enhances market control, discourages counterfeit production, and justifies R&D investments. Narrower claims limit exclusive rights but might enable composite or combination therapies to circumvent protections.

• Strategic Considerations: Absent patent barriers, competitors can develop alternative formulations or delivery methods. Conversely, asserting patent rights might lead to legal disputes, especially in secondary markets.

---

Conclusion: Key Insights on the Patent Landscape for BRPI0619919

• The patent’s scope likely encompasses specific chemical variations, formulations, or therapeutic uses, with broad independent claims supporting fundamental protection.

• The strength of the claims depends on precise patent drafting and prior art landscape navigation, with potential for defensive or offensive patent strategies.

• The patent landscape in this field exhibits high density, requiring continuous monitoring for emerging patents, patent expirations, or potential infringement issues.

• For market players, leveraging this patent requires aligning product development with the protected claims or crafting around narrowly scoped claims.

---

Key Takeaways

• Strategic Positioning: Robust independent claims and clear patent scope serve as key assets in defending market share against generic competition in Brazil.

• Innovation Focus: Maintaining innovation’s edge through supplementary patents—covering incremental improvements—extends protection timelines and market exclusivity.

• Competitive Landscape: A densely populated patent landscape underscores the need for meticulous patent searches and freedom-to-operate assessments before product launches.

• Legal Vigilance: Regular patent monitoring and legal due diligence are essential to mitigate infringement risks and identify licensing opportunities.

• Regulatory Synergy: Aligning patent strategies with regulatory approvals maximizes market protection and minimizes patent invalidation threats.

---

FAQs

1. What types of claims are most common in Brazilian pharmaceutical patents like BRPI0619919?
Most such patents feature independent claims covering the core chemical entity or formulation, with dependent claims specifying particular dosage, manufacturing processes, or uses, creating layered protection and operational flexibility.

2. How does the Brazilian patent landscape for pharmaceuticals compare to regional norms?
Brazilian patent law emphasizes novelty, inventive step, and industrial application, similar to international standards, but with unique procedural requirements, such as examination timelines and specific formalities, affecting patent strategy.

3. Can a patent like BRPI0619919 be challenged or invalidated in Brazil?
Yes. Challenges can be initiated based on prior art disclosures, lack of inventive step, or procedural errors during filing. Stakeholders often pursue oppositions or nullity actions to weaken or revoke patents.

4. How does patent term impact pharmaceutical market exclusivity in Brazil?
Brazil grants patents for 20 years from filing. Patent term remaining affects differentiation strategies—extending exclusivity via secondary filings or data exclusivity periods.

5. What are the next strategic steps for a company holding rights to BRPI0619919?
Key steps include monitoring patent expiration timelines, strengthening claims through supplemental patents, conducting freedom-to-operate analyses, and exploring licensing or litigation opportunities to optimize market position.

---

References

1. Brazilian Patent Office (INPI): Official patent documents and prosecution history.
2. WIPO PATENTSCOPE: For related family patents and international equivalents.
3. Firm's internal patent databases: For competitor patent filings within Brazil.
4. Legal analyses: Recent legal case studies on pharmaceutical patent litigations in Brazil.
5. Regulatory guidelines: Brazilian ANVISA regulations affecting patent life and pharmaceutical approval.

---

In essence, Brazil patent BRPI0619919 exemplifies a strategic intersection of chemical innovation and legal robustness, securing a vital foothold in the competitive pharmaceutical landscape.

Last updated: July 31, 2025